Vomiting and reduced intake increase the risk of ketoacidosis and volume depletion with empagliflozin. The client should hold the drug, contact the prescriber, and seek urgent evaluation for symptoms such as abdominal pain or rapid breathing because ketoacidosis can occur without marked hyperglycemia. Fluid restriction, dose doubling, and stopping prescribed basal insulin can increase harm.
In-depth explanation
Clinical reasoning
Empagliflozin increases urinary glucose loss. Acute illness, vomiting, prolonged fasting, and dehydration can precipitate euglycemic ketoacidosis, so a near-normal glucose value does not make the symptoms safe.
Decision rule
During significant vomiting or poor intake, hold the SGLT2 inhibitor and contact the prescriber. Severe nausea, abdominal pain, dyspnea, or rapid breathing requires urgent assessment for ketoacidosis. Do not independently double the dose or stop prescribed insulin.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.